Inclusion Criteria:

- Imatinib resistant or intolerant Philadelphia chromosome positive CML in blast crisis

- Imatinib resistant or intolerant Philadelphia chromosome positive CML in accelerated
phase

- Imatinib resistant or intolerant Philadelphia chromosome positive CML in chronic
phase

- CML patients who have been treated with an investigational tyrosine kinase inhibitor
who otherwise meet the definition of imatinib resistance or intolerance

- World Health Organization (WHO) performance status ≤ 2

Exclusion Criteria:

- Cytopathologically confirmed central nervous system (CNS) infiltration

- Impaired cardiac function

- Use of therapeutic coumarin derivatives

- Acute chronic liver or renal disease unrelated to tumor

- Other uncontrolled medical conditions

- Treatment with hematopoeitic colony stimulating factors

- Treatment with medications that have potential to prolong the QT interval

- Another malignancy currently clinically significant or requires active intervention

Other protocol-defined inclusion/exclusion criteria may apply.